Search clinical trials for: Oral Potentially Malignant Disorder

Total 164644 results

Cardarelli Hospital

Not yet recruiting

NBI for Early Diagnosis of OPMD/OSCC (NBI_Oral)

Oral Squamous Cell Carcinoma | Oral Potentially Malignant Disorder

Italy
University of Palermo

Recruiting

SYsteMatical Trained learnIng aLgorithms for Oral carcInogenesiS Interpretation by Optical Coherence Tomography (SYMILIS OCT)

Oral Disease | Oral Cancer | Actinic Keratoses | Oral Leukoplakia | Oral Squamous Cell Carcinoma | Oral Lichen Planus | Graft-versus-host-disease | Proliferative Verrucous Leukoplakia | Actinic Cheilitis | Oral Potentially Malignant Disorder | Oral Erythroplakia | Oral Lichenoid Lesion

Italy
Proteocyte Diagnostics Inc.
The University of Texas Health Science Center, Houston; University of Alabama... and other collaborators

Recruiting

Evaluation of Oral Potentially Malignant Disorders (OPMDs) With STRATICYTE™

Mouth Diseases

United States
National Cancer Institute (NCI)

Recruiting

Defining the Natural History of Squamous Cell Carcinoma in Fanconi Anemia

Fanconi Anemia | Inherited Bone Marrow Failure Syndrome

United States
Universidad Rey Juan Carlos

Recruiting

Predictive Value of GOCCLES® Device for Early Diagnosis of Oral Potentially Malignant Disorders

Oral Cancer | Oral Potentially Malignant Disorders

Spain
Dalarna County Council, Sweden
Uppsala University

Recruiting

Oral Cancer Screening for Early Detection of Premalignant Disorders (PMOD) (PMOD)

Mouth Neoplasms

Sweden
University of Milan

Recruiting

Oral Potentially Malignant Disorders: Comparison Between Surgical Treatment and Wait and See Approach

Leukoplakia, Oral

Italy
Proteocyte Diagnostics Inc.

Recruiting

Early Prediction of Oral Cancer by S100A7 Immunohistochemistry Signature-based Assessment

Oral Neoplasm

Canada
University of Santiago de Compostela

Recruiting

Role of the Dentist in the Control of the Alcoholic Habit in Patients With Potentially Malignant Oral Lesions (ALCODENT)

Alcohol Drinking | Oral Potentially Malignant Disorders

Spain
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Multimodal Imaging for Surveillance in Patients With Oral Potentially Malignant Disorders

Dysplasia | Premalignant Lesion | Lip and Oral Cavity Carcinoma | Oral Disorder

United States
Fayoum University

Completed

Salivary LINC00657 as a Diagnostic Biomarker for Oral Squamous Cell Carcinoma

Oral Squamous Cell Carcinoma

Egypt
Institut Pasteur

Completed

Infectious Aetiology of Potentially Malignant Disorders and Squamous Cell Carcinomas of the Oral Cavity (INECOC)

Squamous Cell Carcinoma of the Oral Cavity | Leukoplakia Oral

France
All India Institute of Medical Sciences, New Delhi

Completed

Photographic Evidence of Oral Precancerous Lesions in Current Tobacco and Areca Nut Users Improves Their Quit Rates

Precancerous Conditions

India
University of Zagreb
Croatian Science Foundation

Unknown

Salivary Ap4A, SCCA, TROP2 in Oral Cancer Patients (OCSALTM)

Precancerous Lesions | Oral Cavity Squamous Cell Carcinoma | Saliva Altered
National Taiwan University Hospital

Unknown

The Study of p62/SQSTM1 as a Malignant Transformation Marker for Oral Potentially Malignant Disorders and a Prognostic Marker for Oral Squamous Cell Carcinoma (p62/SQSTM1)

Oral Cancer | Oral Potentially Malignant Disorder | Malignant Disorder | p62/SQSTM1
Ain Shams University

Recruiting

Effectiveness of Topical Magnetite Zinc Oxide Composite Nanoparticles in the Management of Oral Potentially Malignant Lesions

Oral Potentially Malignant Lesions

Egypt
West China Hospital

Not yet recruiting

A Lithium-containing Mouthwash Prevention and Treatment of Oral Mucositis and Dysgeusia in Patients Undergoing Radiotherapy

Head and Neck Squamous Cell Carcinoma | Malignant Head and Neck Tumors

China
Cairo University

Not yet recruiting

Diagnostic Accuracy of Mobile Phone Imaging Compared to Conventional Clinical Examination for Oral Cancer Screening

Oral Cancer | Premalignant Lesion
Aminex Therapeutics, Inc.

Recruiting

Oral AMXT 1501 Dicaprate in Combination With IV DFMO

Melanoma | Cervical Cancer | Cancer | Breast Cancer | Head and Neck Cancer | Gastric Cancer | Colorectal Cancer | Esophageal Cancer | Solid Tumor | Endometrial Cancer | Advanced Cancer | Diffuse Midline Glioma, H3 K27M-Mutant | Papillary Thyroid Cancer | Solid Carcinoma | Mesotheliomas Pleural | Glioma, Malignant | Ovary Cancer and other conditions

United States, Australia
Travera Inc
xCures

Recruiting

Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx) (TraveraRTGx)

Melanoma | Carcinoma, Renal Cell | Carcinoma | Carcinoma, Non-Small-Cell Lung | Carcinoma, Hepatocellular | Carcinoma, Pancreatic | Pancreatic Cancer | Mesothelioma | Cholangiocarcinoma | Carcinoma, Neuroendocrine | Carcinoma, Small Cell | Pleural Effusion, Malignant | Carcinoma, Pancreatic Ductal | Carcinoma of the... and other conditions

United States
Postgraduate Institute of Dental Sciences Rohtak

Not yet recruiting

Evaluation of Periodontal Status and hsCRP Levels in Females With PCOS on CPA/EE Combination Drug Regimen

Polycystic Ovary Syndrome | Periodontitis | Gingivitis

India
Travera Inc
John B. Amos Cancer Center

Not yet recruiting

Defining the Clinical Potential of Mass Response as a Biomarker for Patient Tumor Sensitivity to Drugs

Carcinoma, Renal Cell | Carcinoma | Carcinoma, Non-Small-Cell Lung | Carcinoma, Hepatocellular | Carcinoma, Pancreatic | Mesothelioma | AML | Cholangiocarcinoma | Stage IV Lung Cancer | Carcinoma, Neuroendocrine | Stage IV Breast Cancer | Carcinoma, Ductal | Malignant Ascites | Carcinoma Prostate | Stage III Breast Cancer and other conditions

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Major Complication Rate in Cancer Patients With Neutropenic Fever Potentially Eligible for a Hospital at Home Program

Hematopoietic and Lymphoid Cell Neoplasm | Malignant Solid Neoplasm

United States
AZ Sint-Jan AV

Recruiting

Validation of the O-bridge Protocol: a Prospective, Multicenter Trial

Quality of Life | Mandibular Reconstruction | Benign or Malignant Tumour of the Oral Cavity | Stage III-IV Osteonecrosis | Fixed Dental Restoration

Belgium
Loxo Oncology, Inc.
Eli Lilly and Company

Recruiting

A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors (LIBRETTO-121)

Soft Tissue Sarcoma | Medullary Thyroid Cancer | Papillary Thyroid Cancer | Infantile Fibrosarcoma | Infantile Myofibromatosis

United States, Australia, Japan, Canada, Germany, Korea, Republic of, France, Spain, United Kingdom, Denmark, Italy
Nanobiotix

Recruiting

NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy

Metastatic Renal Cell Carcinoma | Squamous Cell Carcinoma of Head and Neck | Radiotherapy | Immunotherapy | Microsatellite Instability-High Solid Malignant Tumour | Metastasis From Malignant Tumor of Liver | Metastasis From Malignant Tumor of Cervix | Metastasis From Malignant Melanoma of Skin (Disorder) and other conditions

United States
Beijing Stomatological Hospital
Beijing Friendship Hospital; Beijing Chao Yang Hospital; The First Affiliated... and other collaborators

Recruiting

Prospective, Observational, Real-world Oral Malignant Tumors Study (POROMS)

Quality of Life | Postoperative Complications | Head and Neck Neoplasms

China
National Cancer Institute (NCI)

Active, not recruiting

Nivolumab and Ipilimumab in Treating Patients With Rare Tumors

Malignant Solid Neoplasm | Nasopharyngeal Carcinoma | Adenoid Cystic Carcinoma | Transitional Cell Carcinoma | Cholangiocarcinoma | Intrahepatic Cholangiocarcinoma | Chordoma | Gestational Trophoblastic Tumor | Pseudomyxoma Peritonei | Cervical Adenocarcinoma | Vaginal Adenocarcinoma | Vaginal Squamous Cell... and other conditions

United States, Guam
National Cancer Institute (NCI)

Active, not recruiting

Testing Ipatasertib as Potentially Targeted Treatment in Cancers With AKT Genetic Changes (MATCH - Subprotocol Z1K)

Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing LOXO-101 as Potentially Targeted Treatment in Cancers With NTRK Genetic Changes (MATCH - Subprotocol Z1E)

Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing MLN0128 (TAK-228) as Potentially Targeted Treatment in Cancers With TSC1 or TSC2 Genetic Changes (MATCH - Subprotocol M)

Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing Palbociclib (PD-0332991) as Potentially Targeting Treatment in Cancers With CDK4 or CDK6 Amplification (MATCH - Subprotocol Z1C)

Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing BVD-523FB (Ulixertinib) as Potentially Targeted Treatment in Cancers With Genetic Changes (MATCH - Subprotocol Z1L)

Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing Sunitinib as Potentially Targeted Treatment in Cancers With cKIT Genetic Changes (MATCH - Subprotocol V)

Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing Copanlisib as Potentially Targeting Treatment in Cancers With PTEN Expression (MATCH - Subprotocol Z1H)

Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
National Cancer Institute (NCI)

Withdrawn

Testing Nivolumab and BMS-986016 (Relatlimab) as Potentially Targeting Treatment in Cancers That Are LAG-3+ and Have Mismatch Repair Deficiency (MATCH - Subprotocol Z1M)

Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma
National Cancer Institute (NCI)

Active, not recruiting

Testing Afatinib as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH - Subprotocol A)

Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing MLN0128 (TAK-228) as Potentially Targeted Treatment in Cancers With mTOR Genetic Changes (MATCH - Subprotocol L)

Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease

Castleman Disease | Lymphangioleiomyomatosis | Digestive System Carcinoma | Malignant Neoplasm | Recurrent Breast Carcinoma | Recurrent Thyroid Gland Carcinoma | Metastatic Urothelial Carcinoma | Malignant Female Reproductive System Neoplasm | Neurofibromatosis Type 2 | Recurrent Adult Soft Tissue Sarcoma and other conditions

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Exon 14 Deletion Genetic Changes (MATCH - Subprotocol C2)

Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Genetic Changes (MATCH - Subprotocol C1)

Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing GDC-0449 (Vismodegib) as Potentially Targeted Treatment in Cancers With Smoothened or Patched 1 Mutant Tumors (MATCH - Subprotocol T)

Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma | Hematopoietic and Lymphatic System Neoplasm

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing JNJ-42756493 (Erdafitinib) as Potentially Targeting Treatment in Cancers With FGFR Amplifications (MATCH-Subprotocol K1)

Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing AZD9291 as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH-Subprotocol E)

Hematopoietic and Lymphoid Cell Neoplasm | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma
Stony Brook University

Active, not recruiting

Effect H2 Water on QoL of Patients Receiving Radiotherapy for High Grade Gliomas.

Malignant Glioma

United States
OHSU Knight Cancer Institute
Oregon Health and Science University

Terminated

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Primary Myelofibrosis | Anemia | Recurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Anatomic Stage IV Breast Cancer AJCC v8 | Recurrent Acute Myeloid Leukemia | Recurrent Myelodysplastic Syndrome | Refractory Acute Myeloid Leukemia | Refractory Chronic Myelomonocytic Leukemia | Refractory Myelodysplastic... and other conditions

United States
Fayoum University
Cairo University

Completed

Cathelicidin LL-37 Relation to Potentially Malignant Lesions

Oral Potentially Malignant Lesions

Egypt
OHSU Knight Cancer Institute
Genentech, Inc.; Oregon Health and Science University

Withdrawn

SMMART Adaptive Clinical Treatment (ACT) Trial

Anatomic Stage III Breast Cancer AJCC v8 | Recurrent Ovarian Carcinoma | Anatomic Stage IV Breast Cancer AJCC v8 | Advanced Malignant Solid Neoplasm | Advanced Pancreatic Carcinoma | Stage II Pancreatic Cancer AJCC v8 | Stage III Pancreatic Cancer AJCC v8 | Stage IV Pancreatic Cancer AJCC v8 | Recurrent... and other conditions

United States
University Hospital Southampton NHS Foundation...
British Lung Foundation; University of Southampton

Active, not recruiting

Niraparib Efficacy in Patient With Unresectable Mesothelioma (NERO)

Mesothelioma, Malignant

United Kingdom
Cairo University
Olfat Shaker

Completed

Evaluation of the Levels of Salivary Paxillin Oral Premalignant and Malignant Lesions

Comparison of Salivary Paxillin Levels in OPMLs and OSCC to Healthy Subjects

Egypt

Search clinical trials for: Oral Potentially Malignant Disorder

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Luxembourg

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations